CLOs on the Move

Oasis For Orphans

www.o4o.org

 
Oasis For Orphans (o4o.org) is a non-profit organization dedicated to giving children in Kenya hope for a bright future. We believe that education is the key to unlocking opportunities, but when physical and educational needs are not met, the future be...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.o4o.org

  • Wheaton, IL USA 60187
  • Phone: 224.277.5678

Executives

Name Title Contact Details

Similar Companies

Sturdy Memorial Hospital

Sturdy Memorial Hospital Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Sturdy Memorial Hospital Inc. is based in Attleboro, MA. You can find more information on Sturdy Memorial Hospital Inc. at www.sturdymemorial.org

Ready Clinic

Ready Clinic is a privately owned family practice staffed with Nurse Practitioners with locations in Ringgold, Flintstone & Lafayette GA. We provide high-quality care with the understanding that each and everyone deserves to be treated with the highest...

THC

THC.com is the safe place to connect about all things cannabis. THC.com is social media that supports YOU. Get paid on product endoresments!

Blistex

Blistex Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Oak Brook, IL. To find more information about Blistex Inc., please visit www.blistex.com

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.